Periodic Reporting for period 2 - GUT-SEQ (Single-cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease)
Okres sprawozdawczy: 2022-03-01 do 2023-08-31
In aim 2 we are working to unveil critical disease mechanisms, immunological signatures of treatment response and drug-induced immunological changes through longitudinal assessments of human intestinal lymphocytes from IBD patients on novel biological treatments. In this aim we have collected longitudinal samples from 35 IBD patients that have started biologics treatment. Cells have been isolated and biobanked to be analysed once aim 1 is completed.
At the end of aim 1 we expect to have a comprehensive understanding of the relative role of ILCs and T cells in different compartments of the human colon in health and IBD.
For aim 2, biobanking of longitudinal samples from patients treated with biologic therapy is ongoing and we aim to start analyzing the first group of samples at the end of 2023.
At the end of aim 2 we expect to have revealed an immunological signature of successful response to biologics therapy, and identified biomarkers that can aid in predicting which patients will respond to biologics.